| Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis SL Zheng, AJ Roddick Jama 321 (3), 277-287, 2019 | 601 | 2019 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10289), 2049-2059, 2021 | 556* | 2021 |
| Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in … SL Zheng, AJ Roddick, R Aghar-Jaffar, MJ Shun-Shin, D Francis, N Oliver, ... Jama 319 (15), 1580-1591, 2018 | 427 | 2018 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 330 | 2021 |
| Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, ... The Lancet 400 (10365), 1788-1801, 2022 | 308 | 2022 |
| Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials C Reith, C Baigent, L Blackwell, J Emberson, E Spata, K Davies, H Halls, ... The Lancet 400 (10355), 832-845, 2022 | 149 | 2022 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, L Estcourt, L Peto, ... MedRxiv, 2021.03. 09.21252736, 2021 | 99 | 2021 |
| Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials N Staplin, AJ Roddick, J Emberson, C Reith, A Riding, A Wonnacott, ... EClinicalMedicine 41, 2021 | 52 | 2021 |
| Discontinuation and non-publication of clinical trials in cardiovascular medicine AJ Roddick, FTS Chan, JD Stefaniak, SL Zheng International journal of cardiology 244, 309-315, 2017 | 31 | 2017 |
| Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, ... The Lancet Diabetes & Endocrinology 12 (1), 51-60, 2024 | 24 | 2024 |
| Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, A Roddick, E Spata, N Staplin, JR Emberson, ... MedRxiv, 2020.12. 10.20245944, 2020 | 23 | 2020 |
| Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta … SL Zheng, AJ Roddick, S Ayis Diabetes and Vascular Disease Research 14 (5), 400-406, 2017 | 19 | 2017 |
| Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis C Reith, D Preiss, L Blackwell, J Emberson, E Spata, K Davies, H Halls, ... The Lancet Diabetes & Endocrinology 12 (5), 306-319, 2024 | 17 | 2024 |
| UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease WG Herrington, AH Frankel, A Wonnacott, D Webb, A Watt, M Watson, ... UK Kidney Association: Bristol, UK, 2021 | 15 | 2021 |
| UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 UPDATE AJ Roddick, A Wonnacott, D Webb, A Watt, MA Watson, N Staplin, ... BMC nephrology 24 (1), 310, 2023 | 12 | 2023 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021: 2021.03. 09.21252736 PW Horby, L Estcourt, L Peto, JR Emberson, N Staplin, E Spata, ... Publisher Full Text, 0 | 12 | |
| Aspirin therapy for primary prevention: the case for continuing prescribing to patients at high cardiovascular risk—a review R De Caterina, A Aimo, PM Ridker Thrombosis and Haemostasis 120 (02), 199-206, 2020 | 8 | 2020 |
| Meta-analysis of aspirin for primary prevention of cardiovascular events—reply SL Zheng, AJ Roddick JAMA 321 (22), 2244-2245, 2019 | 5 | 2019 |
| Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy CT Trialists’Collaboration Clinical Trials 19 (6), 593-604, 2022 | 4 | 2022 |
| A Versatile, Diels–Alder Reaction-Based Approach to Prenyleudesmane Diterpenoids: A Concise Total Synthesis of Sinupol K Ota, K Kamaike, H Miyaoka Synlett 31 (10), 1007-1010, 2020 | 3 | 2020 |
